BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib

Status: Open to Accrual

Learn more: 

• Clinicaltrials.gov: #NCT05323955

Study Contact: studies@hoosiercancer.org; (317) 921-2050.